LC-MS

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Retrieved on: 
Tuesday, April 16, 2024
LC-MS, Therapy, CMO, Patient, PDE4, Autoimmunity, UC, Fine chemical

Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Key Points: 
  • These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
  • The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period.
  • The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
  • "The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC," said Dr. Mitch Jones, CMO at Palisade Bio.

MOBILion Systems, Inc. Expands European Presence to Support MOBIE Instrument Sales and Customer Success

Retrieved on: 
Tuesday, April 16, 2024
LC-MS, BOKU, Research, Agilent Technologies, LCMS, University, Natural Resources

MOBILion Systems strengthens its European presence by appointing Lucy Woods as Senior Director of European Sales and George Antoniades as Director of European Customer Success.

Key Points: 
  • MOBILion Systems strengthens its European presence by appointing Lucy Woods as Senior Director of European Sales and George Antoniades as Director of European Customer Success.
  • Woods, with her extensive biotechnology background and leadership in commercial management, and Antoniades, with decades-long expertise in global services and customer experience, are set to elevate MOBILion's commercial sales and customer success operations in Europe.
  • "With this expansion, we elevate our customer success efforts to the next level, providing a premium experience that will thrill our customers."
  • To learn more about MOBILion Systems' European expansion, please contact [email protected] .

MOBILion Systems, Inc. Expands European Presence to Support MOBIE Instrument Sales and Customer Success

Retrieved on: 
Tuesday, April 16, 2024
LC-MS, BOKU, Research, Agilent Technologies, LCMS, University, Natural Resources

MOBILion Systems strengthens its European presence by appointing Lucy Woods as Senior Director of European Sales and George Antoniades as Director of European Customer Success.

Key Points: 
  • MOBILion Systems strengthens its European presence by appointing Lucy Woods as Senior Director of European Sales and George Antoniades as Director of European Customer Success.
  • Woods, with her extensive biotechnology background and leadership in commercial management, and Antoniades, with decades-long expertise in global services and customer experience, are set to elevate MOBILion's commercial sales and customer success operations in Europe.
  • "With this expansion, we elevate our customer success efforts to the next level, providing a premium experience that will thrill our customers."
  • To learn more about MOBILion Systems' European expansion, please contact [email protected] .

Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer

Retrieved on: 
Monday, January 29, 2024
CMC, Mass spectrometry, CSO, Biotechnology, Chromatography, GMP, Peptide, Functional, Spacecraft, LC-MS, Antibody, Protein, Dicarboxylic acid, Doctor of Philosophy, Biopharmaceutical, Proteomics, Genentech, Assay, Growth, Fine chemical

CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).

Key Points: 
  • CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).
  • We are thrilled to announce that Dr. Shiaw-Lin (Billy) Wu has joined Crystal Bio as its new co-founder and Chief Scientific Officer (CSO).
  • With over three decades of experience in analytical and bioanalytical analysis of biologics for CMC development, Dr. Wu is a valuable addition to the Crystal Bio team.
  • We are excited to have him on board and look forward to his contributions in driving innovation and growth at Crystal Bio.

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity

Retrieved on: 
Wednesday, January 10, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CITES, Mass spectrometry, UPLC, Multimedia, QPS, Peptide, DMPK, Drug discovery, LC-MS, Laboratory, Therapy, Doctor of Philosophy, Biomarker, HRMS, Oligonucleotide, SFC, Growth, Fine chemical

QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).

Key Points: 
  • QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
  • View the full release here: https://www.businesswire.com/news/home/20240110198636/en/
    Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • (Photo: Business Wire)
    This expansion includes the impressive growth seen in 2023, when QPS installed seven additional UPLC-(HR)MS/MS tandem instruments - four triple quadrupoles, one QTRAP, and two quadrupole time-of-flight high-resolution mass spectrometers (HRMS).
  • QPS Subject Matter Experts are some of the best in the industry and this new equipment will provide the capacity for them to expand their relationships with our important biotech and pharmaceutical clients,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.

Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device

Retrieved on: 
Wednesday, January 3, 2024
Senate, LC-MS, Cannabis, Collection, Workflow, Smoking, Washington State, Health, MSBS, THC, California State Assembly, Mass, Patent, Vaccine, Biomarker, BCU, OTC, LSA

The MSBS substantially simplifies laboratory analysis methods, reduces sample turnaround times (within a few minutes), and provides a truly novel method for drug screening using breath.

Key Points: 
  • The MSBS substantially simplifies laboratory analysis methods, reduces sample turnaround times (within a few minutes), and provides a truly novel method for drug screening using breath.
  • Cannabix is advancing discussions with industry leading forensic laboratory organizations on how to best integrate its novel MSBS hardware into current forensic testing and analysis methods.
  • The new provisional patent covers various novel aspects for efficient analysis of low volatility analytes from human breath developed by the Company.
  • This equipment significantly simplifies laboratory analysis methods, reduces sample turnaround times (thus minimizing operating costs), while maintaining sensitive, precise results.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

Retrieved on: 
Wednesday, December 6, 2023
Shimadzu, Research, Proteomics, Mass spectrometry, Agilent Technologies, LC-MS, Laboratory, SCIEX, Nano, Partnership, Chromatography, 3D printing, Warehouse, Bruker

IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.

Key Points: 
  • IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.
  • This partnership underscores IonOpticks' commitment to broadening the accessibility and application of its top-tier chromatography technologies.
  • Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora Series columns are now seamlessly compatible with Agilent mass spectrometers.
  • This collaboration marks a significant advancement in IonOpticks' drive to empower all researchers with the best chromatography, regardless of the mass spec they are using, with a similar solution for Shimadzu mass specs coming soon.

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

Retrieved on: 
Wednesday, December 6, 2023
Shimadzu, Research, Proteomics, Mass spectrometry, Agilent Technologies, LC-MS, Laboratory, SCIEX, Nano, Partnership, Chromatography, 3D printing, Warehouse, Bruker

IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.

Key Points: 
  • IonOpticks is renowned for its class-leading chromatography solutions, particularly the Aurora Series, which are celebrated for their precision, efficiency, and reliability in protein separation and analysis.
  • This partnership underscores IonOpticks' commitment to broadening the accessibility and application of its top-tier chromatography technologies.
  • Thanks to Newomics' innovative development of the UniESI source, IonOpticks' Aurora Series columns are now seamlessly compatible with Agilent mass spectrometers.
  • This collaboration marks a significant advancement in IonOpticks' drive to empower all researchers with the best chromatography, regardless of the mass spec they are using, with a similar solution for Shimadzu mass specs coming soon.

Cannabis Testing Market to grow by USD 1.50 billion from 2022-2027 | Increasing global awareness about the benefits of cannabis drives the market growth - Technavio

Retrieved on: 
Wednesday, November 8, 2023
Cannabis, Research, ROW, LC-MS, Information management, Software, Segment, Growth, USD, Drug, Retail, Cannabidiol, Geography

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The cannabis testing market size is expected to grow by USD 1.50 billion from 2022 to 2027.
  • Increasing global awareness about the benefits of cannabis drives the growth of the cannabis testing market.
  • Factors like advances in instruments in recent years have increased their adoption in the global cannabis testing market.
  • Growth of the cannabis testing market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of cannabis testing market vendors.